improved information sharing between CBP and its private-sector partners would aid efforts to identify and curtail the sale of counterfeit i...
Our investigation found that the PBM scheme encourages drug makers to spike the drug's list price in order to offer a greater rebate.
The Cantwell-Grassley PBM transparency bill directs the FTC to end well-known and documented PBM practices that drive up consumer price.
Our bill has guardrails. It does not give FTC any new power or regulatory authority.
PBMs are blocking a cheaper product.
It is shocking that a commissioner would choose to resign rather than watch an agency's bipartisan tradition crumble in front of her eyes.
The Cantwell-Grassley PBM Transparency Act directs the FTC to end well-known and documented PBM practices that drive up consumer costs.
I've hauled Big Pharma and PBM executives before the Finance Committee.
I worked at the FTC, and I can tell you that with the Agency's overreach and activism, which will no doubt be difficult to sustain in court,...
It requires the FTC to study pharmaceutical intermediaries and issue a report and recommendations to Congress within one year.
Any true attempt at understanding the factors driving costs must include a look at the broader supply chain.
Today, three PBMs control 80 percent of the market.
I hope this committee will have the same success voting this bill out.
